市場概況

The global market for psoriatic arthritis treatment is projected to reach USD 12.72 10億まで 2029, growing at a CAGR of 6.1% from USD 8.27 億で 2022. Psoriatic arthritis is a chronic inflammatory rheumatic disease that affects up to 30% of psoriasis patients aged 30 に 60. It is more common in women. The exact cause is unknown, but family history and certain risk factors play a role. Diagnosis involves imaging techniques and symptom evaluation. Treatment options include non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, 生物製剤, and emerging therapies. The market is driven by the introduction of new drugs and the demand for improved treatments. IL inhibitors and oral JAK inhibitors show promise. The market has over 25 assets in development, with many in Phase III trials. The introduction of novel therapies will fuel market growth. Targeting inflammatory pathways beyond TNF, such as IL-23/IL-17, has proven effective. Technological advancements are expected to enhance interventions and outcomes in the future.

レポートは市場規模と成長をカバーしています, セグメンテーション, 競争環境, trends and strategies for global psoriatic arthritis market. 利害関係者が現在の市場機会を活用できるように、市場の定量的な分析を提供します。. このレポートはまた、市場動向と主要な競合他社のアプローチに基づいて、機会と戦略の上位セグメントを特定します。.

市場セグメンテーション

市場はさまざまな要因に基づいて分割されます, including drug class, disease type, gender type, 年齢層, severity type, そして地理.
Drug class: interleukin inhibitors, NSAIDs, TNF inhibitors, その他
Disease type: spondylitis, dactylitis, enthesitis
Gender: 男性, 女性
年齢層: 50 years and below, 50 years and above
Severity type: moderate, mild, severe

地理によるセグメンテーション
North America – US
Europe – Germany, フランス, イギリス, イタリア, スペイン
アジア太平洋 – 中国, 日本

TNF-Alpha inhibitors dominate the global psoriatic arthritis treatment market but the fastest growth is expected in interleukin inhibitors. Approvals of drugs like Skyrizi and Cosentyx will drive the market. Women make up a significant portion of the market due to increased risk. Enthesitis holds a significant share but Dactylitis will grow the fastest. Individuals below 50 will make up a substantial portion. Mild form is significant but moderate form will grow the fastest. The United States dominates the market due to affordability, knowledge, and technology. Germany will experience rapid growth due to healthcare access and awareness. Biosimilars in China and Japan will bring changes. China has the highest number of cases, followed by Spain and the U.K. PsA prevalence is increasing in the European Union.

競争環境

Major players in the global psoriatic arthritis treatment market include AbbVie Inc, ジョンソン & ジョンソン, Takeda Pharmaceutical Company Limited, Biogen Inc, UCB SA, Amgen Inc., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly and Company, and Novartis AG. These companies are employing strategies such as collaborations, 買収, geographic expansion, 研究開発, and manufacturing novel drugs to strengthen their product portfolios and compete in the market. Other notable players include Bausch Health Companies Inc., Biocad Biopharmaceutical Co., Bio-Thera Solutions, 株式会社, Eli Lilly and Company, Jiangsu Hengrui Pharmaceuticals Co., 株式会社, Meiji Holdings Co., 株式会社, Sun Pharmaceuticals Industries Limited, とりわけ. These players prioritize research and development to develop advanced psoriatic drugs and maintain their industry position.

報告書の範囲

To analyze and forecast the market size of the global psoriatic arthritis market.
To classify and forecast the global psoriatic arthritis market based on drug class, disease type, gender, 年齢層, severity type, 地理.
To identify drivers and challenges for the global psoriatic arthritis market.
合併などの競争展開を検討するため & 買収, 協定, コラボレーションとパートナーシップ, 等, in the global psoriatic arthritis market.
To identify and analyze the profile of leading players operating in the global psoriatic arthritis market.

このレポートを選択する理由

Gain a reliable outlook of the global psoriatic arthritis market forecasts from 2023 に 2029 シナリオ全体にわたって.
投資対象となる成長セグメントを特定する.
会社概要と市場データを通じて競合他社に先んじる.
Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
3ヶ月間の戦略コンサルティングとリサーチサポート.
シングルユーザーライセンスに提供される印刷認証.